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Abstract
Background: DNA methylation has been shown to play an important role in the silencing of tumor suppressor
genes in various tumor types. In order to have a system-wide understanding of the methylation changes that
occur in tumors, we have developed a differential methylation hybridization (DMH) protocol that can
simultaneously assay the methylation status of all known CpG islands (CGIs) using microarray technologies. A large
percentage of signals obtained from microarrays can be attributed to various measurable and unmeasurable
confounding factors unrelated to the biological question at hand. In order to correct the bias due to noise, we first
implemented a quantile regression model, with a quantile level equal to 75%, to identify hypermethylated CGIs in
an earlier work. As a proof of concept, we applied this model to methylation microarray data generated from
breast cancer cell lines. However, we were unsure whether 75% was the best quantile level for identifying
hypermethylated CGIs. In this paper, we attempt to determine which quantile level should be used to identify
hypermethylated CGIs and their associated genes.
Results: We introduce three statistical measurements to compare the performance of the proposed quantile regression
model at different quantile levels (95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%), using known methylated genes and
unmethylated housekeeping genes reported in breast cancer cell lines and ovarian cancer patients. Our results show
that the quantile levels ranging from 80% to 90% are better at identifying known methylated and unmethylated genes.
Conclusions: In this paper, we propose to use a quantile regression model to identify hypermethylated CGIs by
incorporating probe effects to account for noise due to unmeasurable factors. Our model can efficiently identify
hypermethylated CGIs in both breast and ovarian cancer data.
Background
Epigenetic changes are one of the most common molecu-
lar modifications in cells [1-4]. Among different epige-
netic changes, DNA methylation, the addition of a
methyl group (CH3) to the 5’s cytosine (C) at a CpG site,
plays an important role in gene expression regulation,
transposons silencing, and transcription factor binding
inhibition [5-13]. Therefore, DNA methylation has signif-
icant implications in both normal biology and complex
diseases, such as cancer. In fact, DNA methylation pat-
terns change during tumor growth. These changes may
include regional or genome-wide gain or loss of methyla-
tion [14]. The gain of methylation in cancer is called
hypermethylation, that is, there are more methylation
signals in cancerous cells than in normal cells. On the
other hand, the loss of methylation in cancer is called
hypomethylation, that is, there are fewer methylation sig-
nals in cancerous cells than in normal cells. Numerous
studies have reported that DNA hypermethylation may
cause tumor suppressor gene silencing [15,16]. These
abnormal DNA methylations usually occur at CGIs,
genomic regions rich in CpG sites.
In order to gain an understanding of how genome-wide
(especially CGI) methylation changes affect tumor growth,
numerous microarray protocols have been developed to
simultaneously assay the methylation status of all or partial
regions in the whole genome. Most of these microarray
protocols are developed based upon one of the following
three methods of methylation-dependent treatment of
DNA, each with its advantages and disadvantages [16]:
(1) using methylation sensitive enzymes (such as HpaII
and HinpI) to digest DNA, (2) using specific antibodies or
* Correspondence: shuying.sun@case.edu
1Case Comprehensive Cancer Center, Case Western Reserve University,
Cleveland, Ohio, USA
Full list of author information is available at the end of the article
Sun et al. BMC Bioinformatics 2011, 12:54
http://www.biomedcentral.com/1471-2105/12/54
© 2011 Sun et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.methyl-binding proteins to obtain DNA fragments
enriched with methylation signals, and (3) using sodium
bisulfite to treat denatured DNA to convert unmethylated
cytosine (C) to thymine (T).
In our group, the DMH protocol has been developed
to simultaneously assay the methylation status of all
known CGIs [17,18] using methylation sensitive
enzymes HpaII and HinpI to digest DNA. As opposed
to the earlier DMH protocol in which interrogated sam-
ples were hybridized onto CGI clone arrays with printed
probes averaging 870 bp in length, the current DMH
method assays the sample using CGI tiling arrays with
much shorter probes (45 - 60 bp). Probe affinity, PCR
effects, and many other measurable and unmeasurable
confounding factors due to shorter probe length affect
the observed methylation signals [19].
Previous DMH methylation microarray data analysis
methods either propose an arbitrary log ratio cut off of
1.5 to detect differential methylation [20] or focus on
modeling differential methylation at the probe level [21].
Due to the large impact of probe affinity and many con-
f o u n d i n gf a c t o r s ,as i n g l eh i g hl o gr a t i op r o b em a yn o t
represent true biological signals. Furthermore, it can be
misleading to select differentially methylated promoter
regions based on independent probe signals. In addition,
we are more interested in identifying hypermethylated
regions as opposed to local changes detected by a differ-
ence in a single probe. To meet these biological interests
and needs, we propose the use of a quantile regression
model [22] in order to aggregate CGI probe signals for
the identification of hypermethylated regions. Probe
effects are directly incorporated into this proposed
model. Genes with hypermethylated promoters can be
easily selected according to their associated CGIs. The
idea of using a quantile regression model to identify
methylated CGIs was originally presented by our group
as a poster at the 4th International Symposium on
Bioinformatics Research and Applications. In that pos-
ter, we used a quantile regression model at 75% quan-
tile. Although known methylated and unmethylated
genes can be identified, we were unsure whether 75%
would turn out to be the best quantile level.
In the following sections, we first give a brief intro-
duction to our breast cancer cell line and ovarian cancer
microarray data. We then explain how to use a quantile
regression model to identify hypermethylated CGIs.
Finally, we implement quantile regression models at dif-
ferent quantile levels and compare the performance of
these models using three statistical measurements.
Methods
We use two DMH microarray datasets generated from
40 breast cancer cell lines and 26 ovarian cancer
patients. In particular, we use the 2-color 244K Agilent
arrays hybridized with the test samples (e.g. the breast
cancer cell lines) dye coupled with Cy5 (red) and a com-
mon normal reference dye coupled with Cy3 (green).
The base two log ratio of red over green intensity, log2
(Cy5/Cy3), is used as the observed methylation signal at
each probe. For each array, dye effects are corrected
using the standard within array LOESS normalization in
the Bioconductor package “limma” [23]. We have
explored several normalization methods and found that
the standard LOESS normalization produces more con-
sistent and reliable results than the others (data not
shown).
In a common DMH experiment, it is desirable to
identify CGIs that are hypermethylated in a large per-
centage of the total N samples (e.g., N cancer patients
or N cancer cell lines). Therefore, one important goal of
our DMH microarray study is to identify the CGIs that
are commonly methylated in N samples (N = 40 for
breast cancer data and N = 26 for ovarian cancer data).
In order to control the noise due to measured and
unmeasured factors such as GC content, scanner effects,
and PCR effects that may affect the signals, we apply the
following quantile regression model to each CGI:
Q sample probe sample probe sp s p Ysp(| , ) () ()   =+
where QYsp (τ|samples,p r o b e p)i st h eτ-th conditional
quantile of the observed probe log ratio of sample s at
probe p, samples represents the expected signal from the
sample, and probep denotes the probe effect. In the
above quantile regression model, error terms are
assumed to be independent and distribution-free. The
regression coefficients, especially samples and probep, are
estimated by formulating the quantile regression pro-
blem as a linear program [22]. In fact, both parameter
estimation and inference are conducted using the R
package “quantreg” [22]. An example of using this pack-
a g et of i taq u a n t i l er e g r e s s i o nm o d e lf o ro n eC p G
island has been provided (see Additional file 1).
In the above regression model, we let τ = 95%, 90%,
85%, 80%, 75%, 70%, 65% and 60%. We choose quantile
levels over 50% because we are interested in identifying
hypermethylated regions. In particular, for each sample
(or cell line) effect from the quantile regression output,
there is a p-value indicating whether a sample (or cell
line) shows significant methylation signals at one parti-
cular CGI under the null hypothesis that samples(τ)=0.
The methylation level at each CGI is taken as the num-
b e ro fs a m p l e sf o rw h i c ht h e i ra s s o c i a t e dp - v a l u e sa r e
less than a certain cutoff value p0 w h e r ew el e tp 0 =
0.05, 0.04, 0.03, 0.02, and 0.01. For example, if a CGI
has p-values less than 0.01 in 38 out of 40 breast cancer
arrays, this indicates that this CGI may have very strong
methylation signals across many samples.
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can identify the real methylation signals and to compare
the results of our regression models at different quantile
levels, we use known methylated and housekeeping
genes as “positive” and “negative” controls respectively.
In fact, 30 known hypermethylated genes [24-27] have
been reported for breast cancer, and 32 known hyper-
methylated genes have been reported for ovarian cancer
[28]. For both breast and ovarian cancer, 47 housekeep-
ing genes [29] are selected as “negative” control (i.e.,
known unmethylated genes) due to their low methyla-
tion signals. Recall that the methylation score given to
each CGI is the count of samples with p-value less than
a cutoff point. At each p-value cutoff point p0,w eh a v e
a methylation score for each CGI. Then, there are Nm
and NHK methylation scores with Nm = 30 for breast
cancer data, Nm = 32 for ovarian cancer data, and NHK
= 47 for unmethylated housekeeping genes. We choose
these Nm and NHK genes because each of them is asso-
ciated with at least one CGI. Therefore, this paper
will refer to these genes as Nm methylated and NHK
unmethylated CGIs.
In order to determine if known methylated and
unmethylated CGIs are identified correctly, we use three
different statistical measurements for known methylated
and unmethylated CGIs. The first measurement is the
area under a Receiver Operating Characteristic (ROC)
curve, which we call “AUC” (Area Under Curve). A ROC
is a graphical plot of the sensitivity vs. (1 - specificity) for
a binary classifier system as its discrimination threshold
varies. The ROC can also be represented equivalently by
plotting true positive rates (TPR) vs. false positive rates
(FPR). In this paper, the TPR is the fraction of known
methylated CGIs that are correctly classified as methy-
lated CGIs at a specific methylation score level C0 (0 ≤
C0 ≤ N). The FPR is the fraction of known unmethylated
housekeeping CGIs that are incorrectly classified as
methylated CGIs at a specific methylation score level C0.
The second measurement is the mean difference of
methylation scores of two groups. We call this measure-
ment mean.diff, that is xx mH K − ,w h e r e xm and xHK
are mean methylation scores for known methylated and
unmethylated housekeeping CGIs. The third measure-
ment is the mean difference of methylation scores of two
groups of CGIs divided by their standard deviation. That
is,
xx
sN s N
mH K
m m HK HK
−
+
22 //
,w h e r e xm, xHK, sm
2 and
sHk
2 are the mean and variance of methylation scores for
known methylated and housekeeping CGIs respectively,
we call this measurement “T.stat”. At each quantile level
τ, the larger a statistical measurement is, the more evi-
dent that this quantile level is better at identifying methy-
lated and unmethylated CGIs.
Results
Using both breast and ovarian cancer data sets, we com-
pare the performance of the proposed quantile regres-
sions using three different measurements: AUC, mean.
diff and T.stat. All comparison results are listed in
Tables 1, 2, 3, 4, 5 and 6 with Tables 1, 2 and 3 for
breast cancer data and Tables 4, 5 and 6 for ovarian
cancer data. To have a clear view of these tables, we
have plotted the summary result for each table in Figure
1, where the top three plots are for the three measure-
ment results based on breast cancer data, and the bot-
tom three plots are for the three measurements based
on ovarian cancer data. For all three measurements, the
larger a statistical measurement is, the better that a
quantile regression model is at identifying the two dif-
ferent groups of CGIs (methylated and unmethylated).
In Figure 1, we can see consistent patterns in all three
measurements for both breast and ovarian cancer data.
That is, 90% (cyan), the 85% (dark green), and 80% (red)
are the top 3 lines and these three lines have relatively
small variations across different p-values. Therefore, we
can conclude that any τ between 80% and 90% could
serve well to identify two different groups of CGIs
(methylated and unmethylated). We recommend 85%
for convenience.
In order to determine if our quantile regression model
is better than other available methods, we compare our
method with the previous one that uses a 1.5 cutoff
value at a probe level [20] using our breast cancer data.
A single probe with a large log ratio is not reliable, so
we consider the following cases in each CGI: (1) at least
30% of probes with log ratios greater than 1.5, (2) at
least 50% of probes with log ratios greater than 1.5, and
(3) 100% probes (that is, all probes) with log ratios
greater than 1.5. For the above three cases, the AUC is
0.51, 0.52, and 0.50. These small AUCs are mainly due
to the fact that some methylated CGIs or genes do not
necessarily have many probes with log ratios greater
Table 1 Breast cancer AUC measurement table
τ P < 0.01 p < 0.02 p < 0.03 p < 0.04 p < 0.05
95% 0.865 0.843 0.839 0.839 0.845
90% 0.846 0.843 0.840 0.849 0.850
85% 0.849 0.847 0.846 0.848 0.855
80% 0.868 0.851 0.849 0.849 0.849
75% 0.837 0.825 0.832 0.833 0.843
70% 0.797 0.779 0.788 0.821 0.835
65% 0.753 0.747 0.746 0.754 0.762
60% 0.645 0.669 0.670 0.676 0.681
The first column contains the quantile levels. The second column contains a
sub-table with each sub-column corresponding to the AUC measurement
based on a specific p value and each sub-row corresponding to one quantile
level. Bold numbers are the five largest AUC values in this table.
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probes with relatively large but less than 1.5 log ratios.
We see this pattern very often in our data. As for the
first case, only 3 out of 30 known methylated genes and
4o u to f4 7H Kg e n e sh a v ea tl e a s to n ec e l ll i n ew i t h
more than 30% probes that have log ratios greater than
1.5. As for the second case, only 2 out of 30 known
methylated genes and 1 out of 47 HK genes have at
least one cell line with more than 50% probes that have
log ratios greater than 1.5. As for the third case, 0 out
of 30 known methylated genes and 0 out of 47 HK
genes have at least one cell line with 100% (i.e., all)
probes that have log ratios larger than 1.5. Therefore,
our quantile regression method is certainly much better
than the one that uses 1.5 as a cutoff. In addition, the
1.5 cutoff method may work well for our previous ver-
sion DMH protocol that has longer printed probes
(about 870 bp). However, this arbitrary cutoff method
does not work for the current protocol that uses much
shorter probes (45 ~60 bp).
Discussion
The three measurement plots of breast and ovarian can-
cer data have slightly different patterns. This may be
due to the sample differences between the two datasets.
Breast cancer data are generated from cell lines while
ovarian cancer data are generated from patients. The
breast cancer cell line samples are more homogeneous
than ovarian patient samples. In addition, cancer cell
lines appear to have more methylation than cancer
patients. Furthermore, breast cancer data have 40 arrays
and ovarian cancer data have 26 arrays. This sample size
difference may also explain some inconsistencies
between breast and ovarian cancer data at different
quantile levels due to random variability.
We also observe that the results of the three proposed
measurements show slightly inconsistent patterns. This
may be due to the definition of the three measurements.
AUC and T.stat both consider the variations of methyla-
tion scores. However, mean.diff only considers the dif-
ference of mean methylation scores between methylated
CGIs and unmethylated housekeeping CGIs. Therefore,
the result of AUC and T.stat may be more reliable.
Conclusions
In this paper, we have proposed to use a quantile
regression model to identify hypermethylated CGIs. In
particular, we have incorporated probe effects to take
Table 2 Breast cancer mean.diff measurement table
τ P < 0.01 p < 0.02 p < 0.03 p < 0.04 p < 0.05
95% 13.550 11.197 10.187 9.277 8.788
90% 17.497 16.955 15.899 15.312 14.515
85% 16.030 16.936 17.191 17.357 17.309
80% 13.114 14.165 14.837 15.312 15.694
75% 9.386 10.770 11.798 12.317 13.143
70% 5.732 6.981 7.860 9.204 9.818
65% 3.548 4.589 5.187 5.528 5.765
60% 1.682 2.156 2.618 2.972 3.395
The first column contains the quantile levels. The second column contains a
sub-table with each sub-column corresponding to the mean.diff measurement
based on a specific p value and each sub-row corresponding to one quantile
level. Bold numbers are the five largest mean.diff values in this table.
Table 3 Breast cancer T.stat measurement table
τ P < 0.01 p < 0.02 p < 0.03 p < 0.04 p < 0.05
95% 6.939 5.946 5.549 5.311 5.213
90% 6.680 6.816 6.786 6.869 6.790
85% 6.110 6.443 6.586 6.826 7.097
80% 5.463 5.749 5.982 6.172 6.241
75% 4.810 5.037 5.259 5.482 5.740
70% 4.254 4.313 4.472 4.938 5.147
65% 3.780 3.637 3.796 3.938 4.005
60% 2.686 2.774 2.787 2.872 2.941
The first column contains the quantile levels. The second column contains a
sub-table with each sub-column corresponding to the T.stat measurement
based on a specific p value and each sub-row corresponding to one quantile
level. Bold numbers are the five largest T.stat values in this table.
Table 4 Ovarian cancer AUC measurement table
τ P < 0.01 p < 0.02 p < 0.03 p < 0.04 p < 0.05
95% 0.808 0.800 0.807 0.808 0.796
90% 0.822 0.821 0.815 0.815 0.809
85% 0.823 0.821 0.824 0.823 0.820
80% 0.826 0.846 0.836 0.819 0.812
75% 0.815 0.818 0.802 0.791 0.796
70% 0.774 0.769 0.784 0.780 0.774
65% 0.754 0.759 0.749 0.754 0.766
60% 0.712 0.714 0.672 0.687 0.671
The first column contains the quantile levels. The second column contains a
sub-table with each sub-column corresponding to the AUC measurement
based on a specific p value and each sub-row corresponding to one quantile
level. Bold numbers are the five largest AUC values in this table.
Table 5 Ovarian cancer mean.diff measurement table
τ P < 0.01 p < 0.02 p < 0.03 p < 0.04 p < 0.05
95% 8.122 7.071 6.564 5.870 5.414
90% 11.339 10.331 9.459 8.942 8.229
85% 11.022 11.119 11.099 10.734 10.453
80% 9.226 9.966 10.166 9.909 9.969
75% 6.922 8.138 8.270 8.589 8.878
70% 5.320 6.301 6.908 7.119 7.310
65% 2.991 3.579 4.092 4.326 4.745
60% 1.745 2.407 2.369 2.521 2.682
The first column contains the quantile levels. The second column contains a
sub-table with each sub-column corresponding to the mean.diff measurement
based on a specific p value and each sub-row corresponding to one quantile
level. Bold numbers are the five largest mean.diff values in this table.
Sun et al. BMC Bioinformatics 2011, 12:54
http://www.biomedcentral.com/1471-2105/12/54
Page 4 of 6into consideration the noises from unmeasurable factors.
In order to find out at which quantile levels (95%, 90%,
85%, 80%, 75%, 70%, 65%, and 60%) the proposed quan-
tile regression model is better at identifying known
methylated and unmethylated CGIs, we have introduced
three statistical measurements: AUC, mean.diff, and T.
stat. These measurements show that the quantile level
between 80% and 90% might serve well for identifying
methylated and unmethylated CGIs. Although this paper
has only demonstrated how to identify hypermethylated
CGIs by setting quantiles larger than 50%, our quantile
regression model can also be used to identify hypo-
methylated CGIs with quantiles smaller than 50%, if
desired.
Additional material
Additional file 1: R code for fitting a quantile regression model. This
file gives an example of using the R package “quantreg” to fit a quantile
regression model to identify methylation signals in one CpG island.
Acknowledgements and Funding
This work was supported by the National Science Foundation 0112050 while
SS was a postdoctoral researcher at the Mathematical Biosciences Institute,
The Ohio State University. The authors thank Drs. Terry Speed and Dustin
Potter for valuable suggestions and discussions.
Table 6 Ovarian cancer T.stat measurement table
τ P < 0.01 p < 0.02 p < 0.03 p < 0.04 p < 0.05
95% 5.673 5.295 5.177 4.889 4.758
90% 6.378 6.134 5.953 5.958 5.656
85% 6.253 6.258 6.290 6.293 6.308
80% 5.772 6.194 6.272 6.044 6.010
75% 4.906 5.451 5.523 5.616 5.699
70% 4.400 4.671 4.962 5.002 5.132
65% 3.712 3.949 4.134 4.075 4.307
60% 3.302 3.395 2.967 3.065 3.024
The first column contains the quantile levels. The second column contains a
sub-table with each sub-column corresponding to the T.stat measurement
based on a specific p value and each sub-row corresponding to one quantile
level. Bold numbers are the five largest T.stat values in this table.
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Figure 1 Comparisons of quantile regression models at different quantile levels. We compare results of different quantiles by studying their
performances on identifying two different groups of CGIs (methylated and unmethylated). The legend is: “brown” for τ = 95%, “cyan” for τ = 90%,
“dark green” for τ = 85%, “red” for τ = 80%, “green” for τ = 75%, “blue” for τ = 70%, “black” for τ = 65%, and “purple” for τ = 60%. The top panel
contains three plots for breast cancer data while the bottom panel contains three plots for ovarian cancer data.
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